First in class novel inhibitors targeting a central pathway in fibrosis and inflammation
Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.
Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute, and the Monash Institute of Pharmaceutical Sciences.
​
IP Group helped spin-out the company and provided seed investment.
Our Partners
Fibrosis is a global problem with high unmet need
45%
deaths linked to fibrosis
10%
of the population have a fibrotic condition
0
drugs able to reverse fibrosis
The 5th International IRAP Symposium, Prato Italy
22-25 September 2024.
​
Insulin Regulated Aminopeptidase (IRAP), an enzyme known by many other names, including vasopressinase, oxytocinase, placental leucine aminopeptidase (P-LAP) and angiotensin type 4 receptor (AT4R), plays a role in regulation of glucose uptake as well as degradation of various peptide substrates such as oxytocin. Recent studies indicate IRAP has roles in fibrosis, the immune system, and inflammation.
Inosi Therapeutics is proud to sponsor the IRAP Symposium 2024 to bring together researchers to showcase new discoveries, challenges and therapeutic opportunities in the field of IRAP research.
​
We would be delighted to see you at the IRAP symposium in Prato.
For more information please visit here